• 1. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 2. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 3. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 4. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 5. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers

Research Briefing on 3-Formyl-5-(trifluoromethoxy)phenylboronic acid (CAS: 1451393-39-7) in Chemical Biology and Pharmaceutical Applications

3-Formyl-5-(trifluoromethoxy)phenylboronic acid (CAS: 1451393-39-7) is a boronic acid derivative that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound, characterized by its trifluoromethoxy and formyl functional groups, serves as a critical building block in the synthesis of bioactive molecules, particularly in the development of protease inhibitors and other therapeutic agents. Recent studies have highlighted its role in Suzuki-Miyaura cross-coupling reactions, enabling the construction of complex biaryl structures with high efficiency and selectivity.

One of the most notable advancements involving 3-Formyl-5-(trifluoromethoxy)phenylboronic acid is its application in the development of covalent inhibitors targeting serine proteases. Researchers have leveraged the electrophilic nature of the formyl group to design irreversible inhibitors that form stable bonds with active-site residues, thereby modulating enzymatic activity. A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility in the synthesis of potent thrombin inhibitors, showcasing its potential as a scaffold for anticoagulant therapies.

In addition to its pharmacological applications, 3-Formyl-5-(trifluoromethoxy)phenylboronic acid has been employed in materials science, particularly in the fabrication of boronate ester-based sensors. These sensors exhibit high affinity for diols and sugars, making them valuable tools for glucose monitoring and other diagnostic applications. Recent work by Zhang et al. (2024) explored the compound's use in the development of fluorescent probes for real-time detection of reactive oxygen species (ROS) in cellular environments, underscoring its interdisciplinary relevance.

The synthetic accessibility of 3-Formyl-5-(trifluoromethoxy)phenylboronic acid has also been a focus of recent research. A novel one-pot synthesis method, reported in Organic Letters (2023), significantly improved the yield and purity of the compound by optimizing reaction conditions and minimizing side reactions. This advancement has facilitated its broader adoption in both academic and industrial settings, enabling more efficient scale-up for preclinical studies.

Looking ahead, the unique properties of 3-Formyl-5-(trifluoromethoxy)phenylboronic acid position it as a promising candidate for further exploration in drug discovery and chemical biology. Ongoing research is investigating its potential in targeted protein degradation (PROTACs) and as a warhead in covalent drug design. As the field continues to evolve, this compound is expected to play an increasingly pivotal role in addressing unmet medical needs and advancing therapeutic innovation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)